- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Quiz
Article
Dermatology Times Spot Test: May 24, 2025
Author(s):
Key Takeaways
- Roflumilast foam 0.3% is now FDA-approved for treating plaque psoriasis in patients aged 12 and older, offering a steroid-free option.
- The approval is supported by the ARRECTOR phase 3 trial, highlighting the treatment's efficacy and safety for scalp and body psoriasis.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Dermatology Times presents: Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.
This week, we’ll focus on the US FDA's approval of roflumilast (Zoryve; Arcutis) foam 0.3%, a steroid-free topical treatment for plaque psoriasis of the scalp and body in adults and adolescents aged 12 and older.
Do you have a set of quiz questions to share? Contact editor Emma Andrus at eandrus@mjhlifesciences.com to contribute!
Which of the following best describes the mechanism of action of roflumilast foam 0.3%?
In the phase 3 ARRECTOR trial, what percentage of patients treated with roflumilast foam achieved clear or almost clear skin at 8 weeks based on body IGA scores?
Why is the foam formulation of roflumilast considered particularly beneficial for treating scalp psoriasis?
References
- Arcutis’ Zoryve (roflumilast) topical foam 0.3% approved by US FDA for the treatment of plaque psoriasis in adults and adolescents ages 12 and older. News release. Arcutis Biotherapeutics. Published May 22, 2025. Accessed May 22, 2025. https://www.arcutis.com/arcutis-zoryve-roflumilast-topical-foam-0-3-approved-by-u-s-fda-for-the-treatment-of-plaque-psoriasis-in-adults-and-adolescents-ages-12-and-older/
- Gooderham MJ, Alonso-Llamazares J, Bagel J, et al. Roflumilast foam, 0.3%, for psoriasis of the scalp and body: The ARRECTOR phase 3 randomized clinical trial. JAMA Dermatol. Published online May 07, 2025. doi:10.1001/jamadermatol.2025.1136
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
